Where Will Biogen Be in 5 Years?
Biogen (NASDAQ: BIIB) is a large-cap biotech that has witnessed significant volatility this year, with over 40% price swings in both directions. As it turns out, market participants were essentially betting on the outcome of its ability to advance aducanumab, a potential treatment for Alzheimer's disease, to regulatory approval. That has been a very profitable venture for traders, but not so much for long-term shareholders who are disappointed with spikes in the share price that are coupled with sudden jolts back down to reality.
There is a lot at stake for Biogen, as the company is facing a substantial revenue decline of its already-marketed therapies and is having trouble finding ways to make up those lost sales. Will the company be able to enrich investors for the next five years?
Image source: Getty Images.
Source Fool.com
